Price$1.66-0.01 (-0.60%)
01:30 PM07:00 PM
News · 26 weeks58-38%
2025-10-262026-04-19
Mix4790d
- Insider26(55%)
- SEC Filings11(23%)
- Other4(9%)
- Earnings3(6%)
- Leadership2(4%)
- Offering1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chernett Jorey4 - Neuronetics, Inc. (0001227636) (Issuer)
- PRNeuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference CallMALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5. To listen to the conf
- PROptum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse PractitionersMALVERN, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that Optum/United Healthcare/United Behavioral Health (Optum/UHC/UBH) has updated its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy. Previously, this authority was limited to psychiatrists. The updated policy applies to PMHNPs operating in states where full practice a
- SECSEC Form EFFECT filed by Neuronetics Inc.EFFECT - Neuronetics, Inc. (0001227636) (Filer)
- SECSEC Form DEFA14A filed by Neuronetics Inc.DEFA14A - Neuronetics, Inc. (0001227636) (Filer)
- SECSEC Form DEF 14A filed by Neuronetics Inc.DEF 14A - Neuronetics, Inc. (0001227636) (Filer)
- PRNeuronetics Comments on Letter from Pointillist Family OfficeMALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today issued the following response to the public letter to the Company's Board of Directors (the "Board") from Jorey Chernett at Pointillist Family Office published on April 6, 2026: The Board and management team are committed to acting in the best interests of all shareholders and regularly evaluate opportunities to maximize shareholder value. The Board has reviewed Mr. Chernett
- SECNeuronetics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Neuronetics, Inc. (0001227636) (Filer)
- PRNeuronetics Announces Chief Financial Officer TransitionMALVERN, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company. He will remain with the Company through May 1, 2026 to support an orderly transition. Mr. Pfanstiel's decision to resign is not the result of any dispute or disagreement with the Company or the Company's mana
- PRLargest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS BusinessDelivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic BusinessBLOOMFIELD HILLS, Mich., April 6, 2026 /PRNewswire/ -- Jorey Chernett, the largest independent shareholder of Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") owning approximately 14.12% of outstanding shares, today delivered a letter to the STIM Board of Directors (the "Board") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Company's TMS business. The letter outlines the substantial value that could be delivered to shareholders if a sa
- INSIDERSEC Form 4 filed by Madryn Asset Management, Lp4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Chernett Jorey4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Chernett Jorey4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Chernett Jorey4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Pfanstiel Steven4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Sullivan Keith J4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Macan William Andrew4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Reuvers Daniel L.4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reuvers Daniel L.3 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Chernett Jorey4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Chernett Jorey4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Sullivan Keith J4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Pfanstiel Steven4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Macan William Andrew4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 4 filed by Neuronetics Inc.4 - Neuronetics, Inc. (0001227636) (Issuer)